Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency and Niche of Bulge Stem Cell01:06

Multipotency and Niche of Bulge Stem Cell

A hair follicle or HF is a small part of the skin that produces the hair shaft. Paul Gerson Unna was the first to observe a bulge in the human hair follicle's outer root sheath (ORS). The bulge is present between the sebaceous gland and the arrector pili muscle and is the niche for hair follicle stem cells (HFSCs). The bulge is also a niche for melanocyte stem cells, and their loss results in graying of hair. The HFSCs express Sox9 and Lhx2, which help them maintain stemness and prevent...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

British journal of haematology·2026
Same author

HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.

American journal of hematology·2024
Same author

Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma.

Cancers·2023
Same author

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.

Blood advances·2023
Same author

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.

Annals of hematology·2023
Same author

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.

Blood advances·2023

Related Experiment Video

Updated: Jul 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Hairy Cell Leukemia.

Rossella Riccioni1, Sara Galimberti, Mario Petrini

  • 1Department of Oncology, Transplantation and New Technology in Haematology, University of Pisa, Pisa, Italy.

Current Treatment Options in Oncology
|October 11, 2007
PubMed
Summary
This summary is machine-generated.

Hairy cell leukemia (HCL) is a slow-growing B-cell cancer. Purine analogs like cladribine (2-CdA) and rituximab are effective treatments, inducing high remission rates and improving patient outcomes.

More Related Videos

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Jul 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder.
  • Key features include splenomegaly, pancytopenia, and characteristic lymphocyte morphology.
  • Differential diagnosis relies on immunophenotyping (CD103, CD25, CD11c co-expression).

Purpose of the Study:

  • To review the current understanding and treatment of Hairy cell leukemia.
  • To highlight the efficacy of purine analogs and rituximab in managing HCL.
  • To discuss the impact of novel therapies on disease course and patient outcomes.

Main Methods:

  • Literature review of Hairy cell leukemia treatment strategies.
  • Analysis of treatment outcomes with purine analogs (Cladribine) and rituximab.
  • Evaluation of immunophenotyping in HCL diagnosis.

Main Results:

  • Cladribine (2-CdA) induces over 80% complete remission rates in HCL patients.
  • Rituximab, used after 2-CdA, achieves molecular responses in most cases.
  • Combination therapies (purine analogs, rituximab, chemotherapy) improve clinical course with low toxicity.

Conclusions:

  • Purine analogs are the established treatment of choice for Hairy cell leukemia.
  • Rituximab enhances treatment efficacy, particularly in achieving molecular remission.
  • Modern therapeutic approaches significantly modify HCL prognosis with manageable toxicity.